On February 22, 2024 Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences (Press release, Kura Oncology, FEB 22, 2024, View Source [SID1234640391]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the TD Cowen Health Care conference in Boston at 9:10 a.m. ET / 6:10 a.m. PT and participation in the Leukemia Corporate Panel at 12:50 p.m. ET / 9:50 a.m. PT on March 4, 2024;
A fireside chat at the Leerink Partners Global Biopharma Conference in Miami at 11:20 a.m. ET / 8:20 a.m. PT on March 12, 2024; and
A fireside chat at the Barclays Global Healthcare Conference in Miami at 9:00 a.m. ET / 6:00 a.m. PT on March 14, 2024.
Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following all three events.